Delisting riskPopularity #4,965
Sonoma Pharmaceuticals (SNOA)
Develops and manufactures shelf-stable hypochlorous-acid products for wound, skin, eye, foot, animal, and surface care.
$1.30
After hours+0.01 (+1.17%)
At close$1.28(+2.40%)
In millions of USD, except per-share figures
| In millions | Q2 FY24Sep 2023 | Q3 FY24Dec 2023 | Q4 FY24Mar 2024 | Q1 FY25Jun 2024 | Q2 FY25Sep 2024 | Q3 FY25Dec 2024 | Q4 FY25Mar 2025 | Q1 FY26Jun 2025 | Q2 FY26Sep 2025 | Q3 FY26Dec 2025 | Q4 FY26Mar 2026 | Q1 FY27Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 6 | 4 | 6 | 6 |
| Cost of revenue | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 4 |
| Gross profit | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 2 | 3 |
| 2 | 2 | 3 | 2 | 2 | 2 | 2 | 3 | 2 | 2 | 3 | 3 | |
| Research & development | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| Selling, general & administrative | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Operating income | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | 0 | −1 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | −1 | −1 | −1 | −1 | 0 | −1 | −1 | −1 | −1 | −1 | 0 | 0 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | 0 |
| Net income | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | 0 |
| EPS, basic | −$2.87 | −$1.59 | −$1.37 | −$1.34 | −$0.59 | −$0.63 | −$0.63 | −$0.76 | −$0.32 | −$0.48 | −$0.33 | −$0.09 |
| EPS, diluted | −$2.87 | −$1.59 | −$1.37 | −$1.34 | −$0.59 | −$0.63 | −$0.63 | −$0.76 | −$0.32 | −$0.48 | −$0.33 | −$0.09 |
| Weighted average shares, basic | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 4 |
| Weighted average shares, diluted | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 4 |
| EBITDA | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | 0 | −1 | 0 | 0 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | 0 | −1 | 0 | 0 |
